CTNM vs SRPT · $429.6M cap vs rev $1.13B
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported CTNM revenue for 2024-09-30 was $0. Net income was -$27.7M. CTNM currently screens at market cap $429.6M.
Latest reported SRPT revenue for 2026-06-30 was $1.13B. Net income was $326.1M. Revenue was up 54.9% from 2026-03-31 to 2026-06-30. SRPT currently screens at market cap $2.34B.
CTNM currently screens at market cap $429.6M. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the CTNM and SRPT stock pages for the full models.
Not investment advice.